KemPharm, Inc.: Diferență între versiuni
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei KemPharm, Inc. listata cu simbolul US.KMPH ==Descriere companie== KemPharm, Inc. (KemPharm) (www.kempharm.com) is a specialty pharmaceutical company focused on the discovery and development of prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) technology. KemPharm utilizes its LAT technology to generate prodrug versions of Food and Drug Administration (FDA) approved drugs. The Company's prodrug product candidate...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
KemPharm, Inc. (KemPharm) (www.kempharm.com) is a specialty pharmaceutical company focused on the discovery and development of prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) technology. KemPharm utilizes its LAT technology to generate prodrug versions of Food and Drug Administration (FDA) approved drugs. The Company's prodrug product candidate pipeline is focused on the areas of attention deficit hyperactivity disorder (ADHD), stimulant use disorder (SUD) and central nervous system (CNS) rare diseases, including idiopathic hypersomnia (IH). KemPharm’s lead clinical development candidate for the treatment of SUD, KP879, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate (SDX). In addition, KemPharm has received FDA approval for AZSTARYSTM, a once-daily treatment for ADHD in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone and acetaminophen. | KemPharm, Inc. (KemPharm) (www.kempharm.com) is a specialty pharmaceutical company focused on the discovery and development of prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) technology. KemPharm utilizes its LAT technology to generate prodrug versions of Food and Drug Administration (FDA) approved drugs. The Company's prodrug product candidate pipeline is focused on the areas of attention deficit hyperactivity disorder (ADHD), stimulant use disorder (SUD) and [[CENTRAL|central]] nervous system (CNS) rare diseases, including idiopathic hypersomnia (IH). KemPharm’s lead clinical development candidate for the treatment of SUD, KP879, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate (SDX). In addition, KemPharm has received FDA approval for AZSTARYSTM, a once-daily treatment for ADHD in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone and acetaminophen. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||
Versiunea curentă din 1 octombrie 2024 19:45
Pagina dedicata companiei KemPharm, Inc. listata cu simbolul US.KMPH
Descriere companie[edit | ]
KemPharm, Inc. (KemPharm) (www.kempharm.com) is a specialty pharmaceutical company focused on the discovery and development of prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) technology. KemPharm utilizes its LAT technology to generate prodrug versions of Food and Drug Administration (FDA) approved drugs. The Company's prodrug product candidate pipeline is focused on the areas of attention deficit hyperactivity disorder (ADHD), stimulant use disorder (SUD) and central nervous system (CNS) rare diseases, including idiopathic hypersomnia (IH). KemPharm’s lead clinical development candidate for the treatment of SUD, KP879, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate (SDX). In addition, KemPharm has received FDA approval for AZSTARYSTM, a once-daily treatment for ADHD in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone and acetaminophen.
Grafic actiuni companie[edit | ]